Targeting MAPK Signaling Pathway with Cobimetinib (GDC-0973) Enhances Anti-Leukemia Efficacy of Venetoclax (ABT-199/GDC-0199) in Acute Myeloid Leukemia Models

被引：2

作者：

Han, Lina ^{[1
]}

Zhang, Qi ^{[1
]}

Shi, Ce ^{[2
]}

Cavazos, Antonio ^{[1
]}

Ruvolo, Vivian ^{[1
]}

Leverson, Joel ^{[3
]}

Monique, Dail ^{[4
]}

Phillips, Darren C. ^{[3
]}

Chen, Jun ^{[3
]}

Jin, Sha S. ^{[3
]}

Jacamo, Rodrigo Omar ^{[1
]}

Daver, Naval ^{[1
]}

Jabbour, Elias J. ^{[1
]}

Kantarjian, Hagop M. ^{[1
]}

Andreeff, Michael ^{[1
]}

Sampath, Deepak ^{[4
]}

Konopleva, Marina ^{[1
]}

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA

[2] Harbin Med Univ, Affiliated Hosp 1, Dept Leukemia, Harbin, Peoples R China

[3] AbbVie Inc, N Chicago, IL USA

[4] Genentech Inc, San Francisco, CA USA

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.97.97

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 45 条

[31] ABT-199 (GDC-0199) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): High complete-response rate and durable disease control.
Seymour, John Francis
Davids, Matthew Steven
Pagel, John M.
Kahl, Brad S.
Wierda, William G.
Puvvada, Soham
Gerecitano, John F.
Kipps, Thomas J.
Anderson, Mary Ann
Huang, David C. S.
Rudersdorf, Nikita
Gressick, Lori A.
Montalvo, Nicholas P.
Yang, Jianning
Zhu, Ming
Dunbar, Martin
Cerri, Elisa
Enschede, Sari H.
Humerickhouse, Rod
Roberts, Andrew Warwick
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[32] Preliminary Results of a Phase 1b Study (GO28440) Combining GDC-0199 (ABT-199) with Bendamustine/Rituximab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia
Salles, Gilles Andre
Boyd, Thomas E.
Morschhauser, Franck
Wendtner, Clemens-Martin
Lymp, James
Hilger, James
Vosganian, Gregory
Huang, Jane
Stilgenbauer, Stephan
BLOOD, 2014, 124 (21)
[33] ABT-199 (GDC-0199) combined with rituximab (R) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase 1b study.
Ma, Shuo
Seymour, John Francis
Lanasa, Mark C.
Kipps, Thomas J.
Barrientos, Jacqueline Claudia
Davids, Matthew Steven
Mason-Bright, Tanita
Rudersdorf, Nikita
Yang, Jianning
Munasinghe, Wijith
Zhu, Ming
Cerri, Elisa
Enschede, Sari H.
Humerickhouse, Rod
Roberts, Andrew Warwick
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[34] Targeting BET Family Bromodomain with ABBV-075 and BCL-2 with venetoclax (ABT-199) is synergistic in primary acute myeloid leukemia models
Cai, Tianyu
Kuruvilla, Vinitha Mary
Uziel, Tamar
Zhang, Qi
Han, Lina
Cavazos, Antonio
Shen, Yu
Konopleva, Marina
CANCER RESEARCH, 2018, 78 (13)
[35] Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)
Seymour, John Francis
Davids, Matthew Steven
Pagel, John M.
Kahl, Brad S.
Wierda, William G.
Miller, Thomas P.
Gerecitano, John F.
Kipps, Thomas J.
Anderson, Mary Ann
Huang, David C. S.
Darden, David E.
Gressick, Lori A.
Nolan, Cathy E.
Yang, Jianning
Busman, Todd A.
Graham, Alison M.
Cerri, Elisa
Enschede, Sari H.
Humerickhouse, Rod A.
Roberts, Andrew Warwick
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[36] An immunoassay detecting Bcl-2: Bim and Mcl-1: Bim complexes in the phase 1 monotherapy study of the Bcl-2 inhibitor, ABT-199/GDC-0199, in chronic lymphocytic leukemia patients
Li, Jessica
Chen, Jun
Kadel, Ward
Chyla, Brenda
McKeegan, Evelyn
Punnoose, Elizabeth
Darbonne, Walter
CANCER RESEARCH, 2014, 74 (19)
[37] Selective targeting BET family BDII bromodomain with ABBV-744 and BCL-2 with venetoclax (ABT-199) is synergistic in primary acute myeloid leukemia models
Cai, Tianyu
Kuruvilla, Vinitha
Lin, Xiaoyu
Uziel, Tamar
Lu, Xin
Zhang, Lu
Zhang, Qi
Han, Lina
Cavazos, Antonio
Shen, Yu
Konopleva, Marina
CANCER RESEARCH, 2019, 79 (13)
[38] Selective Targeting BET Family Bdii Bromodomain with Abbv-744 and BCL-2 with Venetoclax (ABT-199) Is Synergistic in Primary Acute Myeloid Leukemia Models
Cai, Tianyu
Kuruvilla, Vinitha Mary
Lin, Xiaoyu
Uziel, Tamar
Lu, Xin
Zhang, Lu
Huang, Xiaoli
Zhang, Qi
Cavazos, Antonio
Han, Lina
Shen, Yu
Konopleva, Marina Y.
BLOOD, 2019, 134
[39] Venetoclax (ABT-199/GDC-0199) Monotherapy Induces Deep Remissions, Including Complete Remission and Undetectable MRD, in Ultra-High Risk Relapsed/Refractory Chronic Lymphocytic Leukemia with 17p Deletion: Results of the Pivotal International Phase 2 Study
Stilgenbauer, Stephan
Eichhorst, Barbara F.
Schetelig, Johannes
Coutre, Steven
Seymour, John F.
Munir, Talha
Puvvada, Soham D.
Wendtner, Clemens-Martin
Roberts, Andrew W.
Jurczak, Wojciech
Mulligan, Stephen
Boettcher, Sebastian
Mobasher, Mehrdad
Zhu, Ming
Chyla, Brenda
Verdugo, Maria
Enschede, Sari Heitner
Cerri, Elisa
Humerickhouse, Rod A.
Gordon, Gary
Hallek, Michael
Wierda, William
BLOOD, 2015, 126 (23)
[40] Bcl-2 Inhibitor ABT-199 (GDC-0199) Monotherapy Shows Anti-Tumor Activity Including Complete Remissions In High-Risk Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
Seymour, John F.
Davids, Matthew S.
Pagel, John M.
Kahl, Brad S.
Wierda, William G.
Miller, Thomas P.
Gerecitano, John F.
Kipps, Thomas J.
Anderson, Mary-Ann
Huang, David C. S.
Rudersdorf, Nikita K.
Gressick, Lori A.
Montalvo, Nicholas P.
Yang, Panning
Busman, Todd A.
Dunbar, Martin
Cerri, Elisa
Enschede, Sari H.
Humerickhouse, Rod A.
Roberts, Andrew W.
BLOOD, 2013, 122 (21)

← 1 2 3 4 5 →